Tools   Select Another Resource Report Type

http://purl.bioontology.org/ontology/HUPSON

Ontology as a basis for shared semantics and interoperability of simulations, of models, of algorithms and of other resources in this domain. The ontology is based on the Basic Formal Ontology, and adheres to the MIREOT principles.

Proper citation: Human Physiology Simulation Ontology (RRID:SCR_010340) Copy   

•   Source: SciCrunch Registry

http://purl.bioontology.org/ontology/LOINC

Ontology of logical observation identifier names and codes (LOINC); Version 2.26; January 2, 2009

Proper citation: Logical Observation Identifier Names and Codes (RRID:SCR_010341) Copy   

•   Source: SciCrunch Registry

https://genomecenter.ucdavis.edu/core-facilities/

Genome Center uses technologies to understand how heritable genetic information of diverse organisms functions in health and disease. Provides research facilities, service cores, and staff for genomics research and training. Core facilities for Bioinformatics,DNA Technologies and Expression Analysis, Metabolomics, Proteomics,TILLING Core,Yeast One Hybrid Services Core.

Proper citation: UC Davis Genome Center Labs and Facilities (RRID:SCR_012480) Copy   

•   Source: SciCrunch Registry

http://www.biolayout.org

BioLayout Express3D is a powerful new tool for the visualization and analysis of networks derived from biological systems. Network-based approaches are becoming increasing popular for the analysis of ''omics and other high dimensional data. Networks can be produced from a wide variety of biological relationships, such as interactions between individuals, disease transmission, sequence similarity, metabolic pathways, protein interactions, pathways, regulatory cascades, gene expression, etc. BioLayout Express3D has been specifically designed for visualization, clustering and analysis of large network graphs in two- and three-dimensional space derived primarily, but not exclusively, from biological data. Sponsors: This resource is supported by BBSRC (BB / F003722 / 1) and the Wellcome Trust (GR077040RP). Keywords: Biology, Tool, Software, visualization, Analysis, Network, Biological, System, Dimentional, Data, Disease, Transmission, Sequence, Metabolic, Pathway, Protein, Interaction, Gene, Expression, Clustering, Analysis,

Proper citation: BioLayout Express 3D (RRID:SCR_007179) Copy   

•   Source: SciCrunch Registry

http://purl.bioontology.org/ontology/DCM

DICOM Controlled Terminology (PS3.16 2013 Annex D)

Proper citation: DICOM Controlled Terminology (RRID:SCR_010302) Copy   

•   Source: SciCrunch Registry

http://www.scienceexchange.com/facilities/university-of-north-carolina-at-chapel-hill

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on April 16,2024. Portal, Core facility.

Proper citation: University of North Carolina at Chapel Hill Labs and Facilities (RRID:SCR_012447) Copy   

•   Source: SciCrunch Registry

http://purl.bioontology.org/ontology/DIAGONT

A computational diagnostic ontology containing 91 elements, including classes and sub-classes, which are required to conduct SR-MA (Systematic Review - Meta Analysis) for diagnostic studies, that will assist in standardized reporting of diagnostic articles. They also report high percentage of agreement among five observers as a result of the inter-observer agreement that they conducted among them to tag 13 articles using the diagnostic ontology. Moreover, they extend their existing repository CERR-N (Center of Excellence in Research Reporting in Neurosurgery) to include diagnostic studies.

Proper citation: Diagnostic Ontology (RRID:SCR_010307) Copy   

•   Source: SciCrunch Registry

http://www.chemservice.com

Chem Service, Inc. offers the convenience, cost savings and reliability of 1,000 Certified Standards Grade Organic Chemicals at your fingertips with our Organic Mini Stockroom Kit. Whether your lab is big or small, disposal fees are a concern. The Organic Mini-stockroom offers you the ability to have 1000 different chemicals at quantities ranging from 100mg to 10gm; thus, reducing disposal costs. Over 95% of their neat Standards Grade materials have a purity of 98.0% or greater, and have been analyzed by three or more (where feasible) independent methods of analysis. These do not require purity corrections when preparing a solution for use with EPA methods. Their more than 13,000 organic and inorganic standards, and solutions, support EPA Methods, ASTM Methods, State UST Methods, Air monitoring Methods, and International Methods. They offer explosive residue standards, PCB congeners, petroleum hydrocarbon standards for the petrochemical industry, pesticide standards, FAME, and vitamin standards for food analysis. Suited for identification of unknowns, product screening, optimal chemical selection and small scale chemical reactions, the O-1000A Organic Ministockroom Kit was designed for laboratories with broad chemical classification and indentification needs. Chem Service, Inc. is registered by ABS Quality Evaluations, Inc., to the internationally recognized requirements of ISO 9001 for design, development, production, distribution and servicing of organic neat and synthetic reference materials.

Proper citation: Chem Service, Inc. (RRID:SCR_008380) Copy   

•   Source: SciCrunch Registry

http://harvester.fzk.de/harvester/

Harvester is a Web-based tool that bulk-collects bioinformatic data on human proteins from various databases and prediction servers. It is a meta search engine for gene and protein information. It searches 16 major databases and prediction servers and combines the results on pregenerated HTML pages. In this way Harvester can provide comprehensive gene-protein information from different servers in a convenient and fast manner. As full text meta search engine, similar to Google trade mark, Harvester allows screening of the whole genome proteome for current protein functions and predictions in a few seconds. With Harvester it is now possible to compare and check the quality of different database entries and prediction algorithms on a single page. Sponsors: This work has been supported by the BMBF with grants 01GR0101 and 01KW0013.

Proper citation: Bioinformatic Harvester IV (beta) at Karlsruhe Institute of Technology (RRID:SCR_008017) Copy   

•   Source: SciCrunch Registry

https://www.medizin.uni-tuebingen.de/en/Students/Institutes/Medical+Psychology.html

The Institute of Medical Psychology and Behavioral Neurobiology in Germany is an institutional portal established at the Faculty of Medicine of the University of Tbingen in 1993. With the assignment of the chair for Medical Psychology and Medical Sociology to Professor Birbaumer the educational task became the instruction of medical students in Medical Psychology and Medical Sociology. Christoph-Dornier-Center of Clinical Psychology at the University of Tobingen Medical Faculty In March 2001, a new institute of the Christoph Dornier Foundation was opened under the direction of Prof. Niels Birbaumer. The aim of this institute is to advance research in behavioral neurobiology and behavioral medicine. The results of the research should be directly translated into treatments. The emphasis in Tbingen is on the treatment of chronic pain and intractable epilepsy, using a combination of biofeedback training and behavioral therapy. Even though a positive effect of biofeedback has been proven in many controlled studies, the method is still far from being accepted in everyday clinical practice. The outpatient department in Tbingen intends to enable access to this treatment to a wider population of patients. Magnetoencephalography(MEG)-Center The MEG-Center (established 1997) is a central research facility at the University of Tbingen. The Center is operated by the Institute of medical psychology and behavioural Neurobiology and hosts a whole-head 151-channel system built by VSMMedtech (www.vsmmedtech.com). In early 2006 in addition to the wholehead MEG an additional special purpose MEG system will be installed in Tbingen (funded by the DFG and Land Baden Wrttemberg). This MEG is dedicated to the investigation of fetal brain signals in utero (fMEG) . The fMEG will be installed at the University Woman Clinic and operated by the staff of the MEG center. This is the first dedicated fMEG system in Europe. Some content on the website is only in German.

Proper citation: Institute of Medical Psychology and Behavioral Neurobiology, University of Tbingen (RRID:SCR_008011) Copy   

•   Source: SciCrunch Registry

http://alzheimers.med.umich.edu/

An Alzheimer's disease center which aims to conduct and promote research on Alzheimer's disease and enhance public and professional understanding of dementia through education and outreach efforts. The MADC promotes clinical research on memory and aging which involves the direct use of research volunteers, biomarkers, and other clinical data collected through the University of Michigan Memory and Aging Project.

Proper citation: Michigan Alzheimer's Disease Center (RRID:SCR_008773) Copy   

•   Source: SciCrunch Registry

http://www.parkinsoninfo.org

THIS RESOURCE IS NO LONGER IN SERVICE, documented on May 18th, 2016. A foundation that was founded in 2001, and sponsors academic centers throughout the US. The MIchael Stern Parkinson's Research Foundation focuses its efforts mainly on finding the causes of the disease, finding effective treatments, and discovering a cure for the disease. The foundation is notably looking into dopamine and its effects on neural connections, as well its possibility to be used for treatment.
Dr. Greengard has assembled a close knit group of more than 25 outstanding scientists who are focused on translating the fundamental understandings about the dopamine system into new treatments for Parkinson's. The core team of researchers is based at the Stern Foundation laboratory on the campus of The Rockefeller University interacts continually with collaborators from the United Kingdom, France, Sweden, Italy, Japan and Korea. This global presence ensures that no promising research lead is overlooked, and that progress can be made on multiple fronts simultaneously. As the Foundation grew it was able to expand its support for critical neurological research to two other institutions, Harvard University's McLean Hospital, where we support the research of Dr. Ole Isacson whose research lab, The Stern Center for Neuroregeneration Research is using gene therapy to protect the most vulnerable neurons in PD models; and the Institute for Neurodegenerative Disorders, where Yale Professors Dr. Ken Marek and Dr. John Seibyl are developing novel tools for early detection and monitoring of Parkinson's disease by studying physiologic, biochemical and neuroimaging biomarkers for non-dominergic manifestations of Parkinsonism. :NIF thanks the Parkinson's Disease Foundation, http://www.pdf.org for their referral of this resource to us.

Proper citation: Michael Stern Parkinsons Research Foundation (RRID:SCR_008098) Copy   

•   Source: SciCrunch Registry

http://purl.bioontology.org/ontology/TMO

A high level patient-centric ontology for the pharmaceutical industry. The ontology should enable silos in discovery research, hypothesis management, experimental studies, compounds, formulation, drug development, market size, competitive data, population data, etc. to be brought together. This would enable scientists to answer new questions, and to answer existing scientific questions more quickly. This will help pharmaceutical companies to model patient-centric information, which is essential for the tailoring of drugs, and for early detection of compounds that may have sub-optimal safety profiles. The ontology should link to existing publicly available domain ontologies.

Proper citation: Translational Medicine Ontology (RRID:SCR_010439) Copy   

•   Source: SciCrunch Registry

http://purl.bioontology.org/ontology/BP-METADATA

Ontology that represents the structure that BioPortal uses to represent all of its metadata (ontology details, mappings, notes, reviews, views)

Proper citation: BioPortal Metadata Ontology (RRID:SCR_010167) Copy   

•   Source: SciCrunch Registry

https://www.amazon.com/How-Brain-Works-Mark-Dubin/dp/0632044411

THIS RESOURCE IS NO LONGER IN SERVCE, documented September 2, 2016. Is the Brain (Like) a Computer is an e-book written by Prof. Mark Dubin. It consists of the following: Introduction. Why do we consider the relationship of brains and computers and what does this have to do with consciousness? What's a Brain Made Of? A thought experiment. Test Drive a Turing Machine. A theoretical approach. Interim Summary. Many of the main pages have links to additional information. When you click on one of those links a NEW page will open ON TOP of the page you are clicking from. This convention is adopted so that you can look at the additional information and then easily return to the main page you got there from.

Proper citation: Is the Brain (Like) a Computer (RRID:SCR_008809) Copy   

•   Source: SciCrunch Registry

http://www.nimh.nih.gov/funding/clinical-trials-for-researchers/practical/step-bd/index.shtml

A long-term outpatient study designed to find out which treatments, or combinations of treatments, are most effective for treating episodes of depression and mania and for preventing recurrent episodes in people with bipolar disorder. This study has been completed. (2005) STEP-BD is evaluating all the best-practice treatment options used for bipolar disorder: mood-stabilizing medications, antidepressants, atypical antipsychotics, and psychosocial interventions - or talk therapies - including Cognitive Behavioral Therapy, Family-focused Therapy, Interpersonal and Social Rhythm Therapy, and Collaborative Care (psychoeducation). There are two kinds of treatment pathways in STEP-BD, and participants may have the opportunity to take part in both. The medications and psychosocial interventions provided in these pathways are considered among the best choices of treatment for bipolar disorder in everyday clinical practice. In the Best Practice Pathway, participants are followed by a STEP-BD certified doctor and all treatment choices are individualized. Everyone enrolled in STEP-BD may participate in this pathway. Participants and their doctors work together to decide on the best treatment plans and to change these plans if needed. Also, anyone who wishes to stay on his or her current treatment upon entering STEP-BD may do so in this pathway. Adolescents and adults age 15 years and older may participate in the Best Practice Pathway. For adults age 18 and older, another way to participate is in the STEP-BD Randomized Care Pathways. Depending on their symptoms, participants may be offered treatment in one or more of these pathways during the course of the study. The participants remain on mood-stabilizing medication. However, because doctors are uncertain which of several treatment strategies work best for bipolar disorder, another medication and/or talk therapy may be added. Each Randomized Care Pathway involves a different set of these additional treatments. Unlike in the Best Practice Pathway, the participants in the Randomized Care Pathways are randomly assigned to treatments. Also, in some cases, neither the participant nor the doctor will be told which of the different medications is being added. This is called a double-blind study and is done so that the medication effects can be evaluated objectively, without any unintended bias that may come from knowing what has been assigned. Participants will not be assigned medications that they have had bad reactions to in the past, that they are strongly opposed to, or that the doctor feels are unsuitable for them. The medication(s) participants may be randomly assigned to in the Randomized Care Pathways are free of charge. There are other treatment options for participants if they do not respond well to the treatment assigned to them. Also, participants may return to the Best Practice Pathway at any time. About 1,500 individuals will be enrolled in at least one Randomized Care Pathway during their period of participation in STEP-BD. It is important to note that STEP-BD provides continuity of care. For example, if a participant starts out in the Best Practice Pathway and later chooses to enter one of the Randomized Care Pathways, he or she continues with the same STEP-BD doctor and treatment team. Then, after completing the Randomized Care Pathway, the participant may return to the Best Practice Pathway for ongoing, individually-tailored treatment. Follow the link to view study info at Clinicaltrials.gov, http://www.clinicaltrials.gov/ct/show/NCT00012558?order=1

Proper citation: Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) (RRID:SCR_008844) Copy   

•   Source: SciCrunch Registry

http://www.neurosci.umn.edu/

The graduate program in neuroscience at the University of Minnesota is a large, multidisciplinary program consisting of over 100 faculty members from all parts of the University of Minnesota, over 25 departments from over 10 colleges. The multidisciplinary nature of the Ph.D. program is one of its most significant strengths.

Proper citation: University of Minnesota Graduate Program in Neuroscience (RRID:SCR_007516) Copy   

•   Source: SciCrunch Registry

http://www.topqbiosystems.com

Contract research organization that performs IHC detection of antigens in tissue and cell samples. Some target antigens are difficult-to-detect because of various reasons. We offer the following quality IHC services with the primary antibodies provided by customers: -Primary antibody selections -Formalin fixed paraffin embedded (FFPE) tissue sample sectioning -Processing condition optimizations -IHC single or double staining (colorimetric or fluorescent) FFPE slides TMA slides -IHC data analysis

Proper citation: TopQ BioSystems (RRID:SCR_012424) Copy   

•   Source: SciCrunch Registry

http://www.scienceexchange.com/facilities/enzymatics

Enzymatics is an independent, ISO 13485:2003 certified OEM manufacturer of enzymes that brings to the marketplace a unique, quality oriented, and customer focused approach to protein production. The company was founded in 2006 to specifically address the needs of commercial entities engaged in the development, manufacture, and distribution of platforms dedicated to nucleic acid identification. Enzymes are critical to the performance of these applications and the industry''s relentless pursuit of higher performance emphasizes the need for analytical reagent purity and absolute production consistency. Operating from the perspective that we are a manufacturing division of our customer, Enzymatics consistently delivers the highest quality and value enzymes, leveraging them to drive customer success via a partnership business model; and our tremendous success confirms the need in the marketplace for a dedicated partner in the realm of enzyme technologies.

Proper citation: Enzymatics (RRID:SCR_012545) Copy   

•   Source: SciCrunch Registry

http://www.cerep.fr/Cerep/Users/pages/ProductsServices/InVitro.asp

Cerep offers a panel of over 630 validated in vitro pharmacological assays that cover a broad range of targets including receptors, ion channels, transporters, enzymes and second messengers. These assays are used to identify lead compounds, to define mechanism of action, and to identify off-target activities. All assays are available on an ad hoc basis. At any time, clients can select one or more assays to be tested against one or more compounds at one or more concentrations. In addition to ad hoc access, client specific and Cerep profiles are available. Client specific profiles can be adapted using any of the over 630 Cerep assays. Standard Profiles are designed by Cerep and available to all clients. The Standard Profiles are a rapid and cost effective way of prioritizing the most promising compounds in the lead selection process. Benefiting from increased efficiency generated from optimized processes, Cerep is happy to expand custom made profiles clients can design at set prices. While offering more flexibility, clients are able to select among predefined lists of functional GPCR, kinase and binding assays. Keywords: In vitro, Pharmacology, Assay, Target, Receptor, Ion channel, Transporter, Enzyme, Mechanism, Hoc, Compound, Kinase, GPCR, Secondary messenger,

Proper citation: CEREP: In Vitro Pharmacology (RRID:SCR_007233) Copy   

•   Source: SciCrunch Registry